Codiak BioSciences, Inc.
CDAKDelisted May 2, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001659352
Codiak BioSciences, Inc. was delisted on May 2, 2023; its insiders filed their last Form 4 on Mar 30, 2023; 27 institutions reported holding it in 13F filings for Q1 2023, worth $1.44M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:52 PM ET
Revenue flow, FY2021
Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2021: $37.2M (162.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 |
|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K |
| Reported | Mar 10, 2022 | Mar 17, 2021 |
| Revenue | $22.9M | $2.92M |
| Operating expenses | $92.5M | $93.8M |
| Research and development | $64.9M | $74.0M |
| Selling, general and administrative | $27.6M | $19.9M |
| Operating income | -$69.5M | -$90.9M |
| Interest expense | $2.70M | $1.91M |
| Income tax | $0 | $0 |
| Net income | -$37.2M | -$91.7M |
| Margins and growth | ||
| Operating margin | -303.2% | -3119.0% |
| Net margin | -162.0% | -3144.6% |
| Revenue growth, year over year | +686.8% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 |
|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K |
| Reported | Mar 10, 2022 | Mar 17, 2021 |
| Cash and equivalents | $76.9M | $88.9M |
| Total current assets | $90.2M | $93.8M |
| Property, plant and equipment | $23.5M | $31.4M |
| Total assets | $171.7M | $151.3M |
| Accounts payable | $1.84M | $2.02M |
| Total current liabilities | $27.2M | $17.7M |
| Total liabilities | $118.2M | $136.8M |
| Shareholders' equity | $53.5M | $14.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 |
|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K |
| Reported | Mar 10, 2022 | Mar 17, 2021 |
| Operating cash flow | -$74.1M | -$63.4M |
| Capital expenditures | $3.25M | $21.1M |
| Free cash flow | -$77.4M | -$84.4M |
| Depreciation and amortization | $5.34M | $4.40M |
| Stock-based compensation | $10.1M | $7.08M |
| Investing cash flow | -$3.25M | $52.0M |
| Financing cash flow | $65.4M | $89.6M |
| Net change in cash | -$12.0M | $78.2M |
| Ratio | ||
| Stock-based compensation, % of revenue | 44.2% | 242.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.